|
1
|
Govindan R, Page N, Morgensztern D, Read
W, Tierney R, Vlahiotis A, Spitznagel EL and Piccirillo J: Changing
epidemiology of small-cell lung cancer in the United States over
the last 30 years: Analysis of the surveillance, epidemiologic, and
end results database. J Clin Oncol. 24:4539–4544. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen J, Jiang R, Garces YI, Jatoi A,
Stoddard SM, Sun Z, Marks RS, Liu Y and Yang P: Prognostic factors
for limited-stage small cell lung cancer: A study of 284 patients.
Lung Cancer. 67:221–226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pietanza MC, Kadota K, Huberman K, Sima
CS, Fiore JJ, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny
AI, et al: Phase II trial of temozolomide in patients with relapsed
sensitive or refractory small cell lung cancer, with assessment of
methylguanine-DNA methyltransferase as a potential biomarker. Clin
Cancer Res. 18:1138–1145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zauderer MG, Drilon A, Kadota K, Huberman
K, Sima CS, Bergagnini I, Sumner DK, Travis WD, Heguy A, Ginsberg
MS, et al: Trial of a 5-day dosing regimen of temozolomide in
patients with relapsed small cell lung cancers with assessment of
methylguanine-DNA methyltransferase. Lung Cancer. 86:237–240. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
National Comprehensive Cancer Network, .
NCCN Clinical Practice Guidelines in OncologySmall Cell Lung Cancer
version 2.2017. Fort Washington; PA: 2016
|
|
6
|
Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L,
Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, et al: Epidermal growth
factor receptor mutations and their correlation with gefitinib
therapy in patients with non-small cell lung cancer: A
meta-analysis based on updated individual patient data from six
medical centers in mainland China. J Thorac Oncol. 2:430–439. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang XW, Ciccarino P, Rossetto M,
Boisselier B, Marie Y, Desestret V, Gleize V, Mokhtari K, Sanson M
and Labussière M: IDH mutations: genotype-phenotype correlation and
prognostic impact. Biomed Res Int. 2014:5402362014.PubMed/NCBI
|
|
9
|
SongTao Q, Lei Y, Si G, YanQing D, HuiXia
H, XueLin Z, LanXiao W and Fei Y: IDH mutations predict longer
survival and response to temozolomide in secondary glioblastoma.
Cancer Sci. 103:269–273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: Introduction to The 2015 World Health
Organization Classification of Tumors of the Lung, Pleura, Thymus,
and Heart. J Thorac Oncol. 10:1240–1242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Taylor JW and Schiff D: Treatment
considerations for MGMT-unmethylated glioblastoma. Curr Neurol
Neurosci Rep. 15:5072015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Y, Chen X, Zhang Z, Li S, Chen B, Wu
C, Wang L, Zhang X, Wang J, Chen L and Jiang T: Comparison of the
clinical efficacy of temozolomide (TMZ) versus nimustine
(ACNU)-based chemotherapy in newly diagnosed glioblastoma.
Neurosurg Rev. 37:73–78. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cabrini G, Fabbri E, Lo Nigro C, Dechecchi
MC and Gambari R: Regulation of expression of O6-methylguanine-DNA
methyltransferase and the treatment of glioblastoma (Review). Int J
Oncol. 47:417–428. 2015.PubMed/NCBI
|
|
14
|
Wick W, Weller M, van den Bent M, Sanson
M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M and
Reifenberger G: MGMT testing-the challenges for biomarker-based
glioma treatment. Nat Rev Neurol. 10:372–385. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miglio U, Mezzapelle R, Paganotti A,
Veggiani C, Mercalli F, Mancuso G, Gaudino E, Rena O, Buosi R and
Boldorini R: Frequency of O6-methylguanine-DNA methyltransferase
promoter methylation in cytological samples from small cell lung
cancer. Diagn Cytopathol. 43:947–952. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ohka F, Ito M, Ranjit M, Senga T, Motomura
A, Motomura K, Saito K, Kato K, Kato Y, Wakabayashi T, et al:
Quantitative metabolome analysis profiles activation of
glutaminolysis in glioma with IDH1 mutation. Tumour Biol.
35:5911–5920. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stein EM: IDH2 inhibition in AML: Finally
progress? Best Pract Res Clin Haematol. 28:112–115. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tian GY, Zang SF, Wang L, Luo Y, Shi JP
and Lou GQ: Isocitrate Dehydrogenase 2 Suppresses the Invasion of
Hepatocellular Carcinoma Cells via Matrix Metalloproteinase 9. Cell
Physiol Biochem. 37:2405–2414. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang J, Zhao YY, Li JF, Guo CC, Chen FR,
Su HK, Zhao HF, Long YK, Shao JY, To SS and Chen ZP: IDH1 mutation
detection by droplet digital PCR in glioma. Oncotarget.
6:39651–39660. 2015.PubMed/NCBI
|
|
20
|
Xia L, Wu B, Fu Z, Feng F, Qiao E, Li Q,
Sun C and Ge M: Prognostic role of IDH mutations in gliomas: A
meta-analysis of 55 observational studies. Oncotarget.
6:17354–17365. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Houillier C, Wang X, Kaloshi G, Mokhtari
K, Guillevin R, Laffaire J, Paris S, Boisselier B, Idbaih A,
Laigle-Donadey F, et al: IDH1 or IDH2 mutations predict longer
survival and response to temozolomide in low-grade gliomas.
Neurology. 75:1560–1566. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang JB, Dong DF, Wang MD and Gao K: IDH1
overexpression induced chemotherapy resistance and IDH1 mutation
enhanced chemotherapy sensitivity in Glioma cells in vitro and in
vivo. Asian Pac J Cancer Prev. 15:427–432. 2014. View Article : Google Scholar : PubMed/NCBI
|
